B Group Inc. Buys Shares of 350,000 Insmed Incorporated (NASDAQ:INSM)

B Group Inc. purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 350,000 shares of the biopharmaceutical company’s stock, valued at approximately $24,164,000. Insmed makes up 14.8% of B Group Inc.’s investment portfolio, making the stock its 3rd largest position.

Other institutional investors have also made changes to their positions in the company. Jennison Associates LLC increased its position in Insmed by 0.6% during the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after buying an additional 4,560 shares during the last quarter. Capital CS Group LLC acquired a new position in shares of Insmed during the 4th quarter valued at about $586,000. Tidal Investments LLC raised its stake in shares of Insmed by 447.0% in the 3rd quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company’s stock valued at $1,759,000 after acquiring an additional 19,696 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in Insmed by 237.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company’s stock worth $4,115,000 after purchasing an additional 41,918 shares during the last quarter. Finally, abrdn plc boosted its position in Insmed by 159.5% during the fourth quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company’s stock worth $19,998,000 after purchasing an additional 178,041 shares during the period.

Insmed Stock Up 3.3 %

Shares of INSM stock opened at $72.53 on Monday. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market cap of $13.19 billion, a P/E ratio of -12.97 and a beta of 1.07. The stock has a fifty day moving average price of $75.34 and a 200 day moving average price of $73.61.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on INSM shares. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Royal Bank of Canada reissued an “outperform” rating and set a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Morgan Stanley raised their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $94.00.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the sale, the insider now owns 97,083 shares of the company’s stock, valued at $7,766,640. This represents a 48.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the completion of the transaction, the chief executive officer now directly owns 379,534 shares of the company’s stock, valued at approximately $29,580,879.96. This represents a 4.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 471,797 shares of company stock worth $37,621,239. 3.00% of the stock is currently owned by insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.